Full Press Release Details
BridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1).
BBIO
BridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Key Takeaway: BridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Price reaction · baseline $28.01 (2024-05-31 close) · 2 other BBIO headline(s) in the window, move may be shared
day 0 close · peak
+3.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis